^
    Back
    Association details:
    Biomarker:RNASE7 elevation
    Cancer:Hepatocellular Cancer
    Drug Class:ROS1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Hepatol
    Title:

    Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma

    Published date:
    10/05/2020
    Excerpt:
    In both HCC PDX and orthotopic mouse models, ROS1 inhibitor treatment markedly suppressed RNase7-induced tumorigenesis and led to decreased plasma RNase7 level with tumor shrinkage in mice….RNase7 serves as a high-affinity ligand for ROS1, and plasma RNase7 has the potential to function as a biomarker to stratify HCC patients for anti-ROS1 treatment.
    DOI:
    10.1016/j.jhep.2020.09.030